The thoracic oncology community is discussing early data for a new first-line combination in KRAS G12C NSCLC. A study of the FAK inhibitor ifebemtinib plus the KRAS G12C inhibitor garsorasib showed a response rate of 82% and a median PFS of 22.3 months. There is also discussion around the expanding role of ADCs, emphasizing the need to assess HER2 and c-Met protein expression at initial diagnosis.
“Study of first line ifebemtinib (FAK inhibitor) plus garsorasib (KRAS G12C inhibitor) in KRAS G12C NSCLC @LancetRespirMed. RR 82%, mPFS 22.3m, mOS 27.8m.”
— @StephenVLiu · KRAS G12C NSCLC · View post ↗
“Beyond identifying oncogenic drivers to target Lung patients, ADCs can address our #HER2 and #cMet IHC-overexpressing NSCLC patients. It is now crucial to assess protein expression at initial diagnosis !”
— @dplanchard · ADCs and Biomarkers · View post ↗📌 Amplified by @KolPulseAI
“EP-Based Combinations Improve PFS, While DLL3 Expression in 87.5% of Tumors Positions DLL3 Targeted Therapy as a Promising Future Strategy.”
— @Dr_Oncologista · Transformed EGFR NSCLC · View post ↗The breast oncology community is discussing the publication of the phase III OPTIMAL trial, which showed oral paclitaxel (DHP107) is non-inferior to weekly IV paclitaxel for progression-free survival in HER2-negative metastatic breast cancer. The oral formulation also resulted in less neuropathy. Other conversations include the potential for Anti-Müllerian Hormone (AMH) to predict chemotherapy benefit in premenopausal patients and the clinical integration of SERDs.
“oral paclitaxel (DHP107) is non-inferior to weekly IV paclitaxel in HER2− metastatic breast cancer — same efficacy, less neuropathy, no infusion.”
— @sbkim712 · OPTIMAL trial · View post ↗📌 Amplified by @KolPulseAI
“Emerging evidence suggests Anti-Müllerian Hormone (AMH) may predict which premenopausal women with HR+/HER2− early breast cancer derive the greatest benefit from chemotherapy.”
— @K_Yadavir · AMH as a biomarker · View post ↗
“SERD Wars: Clinical Integration of Emerging Endocrine-Directed and Precision Therapies in Breast Cancer | JCO Oncology Practice”
— @jamecancerdoc · SERDs · View post ↗📌 Amplified by @KolPulseAI
Quiet today — no notable KOL discussion in the last 48 hours.
With perioperative enfortumab vedotin + pembrolizumab now FDA-approved for muscle-invasive bladder cancer, the GU community's discussion has shifted to next steps — patient selection and whether bladder-preservation strategies can build on the regimen. (The approval itself led yesterday's digest.)
“A few months after ASCO GU, EVP is now FDA approved for cisplatin-eligible MIBC! 🎉 Now many trials looking at bladder preservation in pts w/ cCR inc:”
— @DrKarineTawagi · MIBC treatment evolution · View post ↗📌 Amplified by @KolPulseAI
“FDA approves neoadjuvant + adjuvant EV+pembro for muscle-invasive bladder cancer, now regardless of cisplatin eligibility. The first non-platinum regimen in ~25 years to beat cisplatin-based NAC head to head.”
— @Markuseckstein3 · Neoadjuvant EV+Pembro approval · View post ↗📌 Amplified by @KolPulseAI
“After 4 cycles of neoadj enfortumab vedotin/pembro in a patient with cT3N0 muscle-invasive bladder cancer, the patient no longer wishes to undergo surgery. What would be your next?”
— @DrYukselUrun · MIBC clinical dilemma · View post ↗Myeloma KOLs are discussing a paper identifying predictors of delayed cilta-cel neurotoxicity, and the open question of whether doublet maintenance after autologous stem-cell transplant improves outcomes. (The subcutaneous isatuximab on-body injector approval led yesterday's digest.)
“Rapid peak cilta-cel expansion is associated with delayed neurotoxicity (DNT) in myeloma; peak ALC ≥3000/uL, or ≥2500/uL following a daily twofold increase, predicted elevated DNT risk (sensitivity 81%, specificity 59%)”
— @Myeloma_Doc · Cilta-cel neurotoxicity · View post ↗
“Does doublet maintenance after ASCT improve outcomes in multiple myeloma?”
— @AJPortuguese · Post-ASCT maintenance · View post ↗The hematology community is discussing topics from recent educational meetings, with a focus on investigational therapies in acute leukemia. Conversations highlighted advances in menin inhibitors and the upcoming RAVEN study for newly diagnosed KMT2Ar AML. Other key topics included clinical updates in BPDCN and a review of CAR-T and systemic treatment options for relapsed/refractory DLBCL.
“Always great to highlight the incredible advances of menin inhibitors and excited to discuss our upcoming RAVEN 🐦⬛ Study for newly diagnosed younger/fit KMT2Ar AML 🙏”
— @LeukDocJZ · Menin inhibitors in AML · View post ↗
“highlighting our rapidly growing international 🌍#BPDCN research field! #CD123 #BCL2 #TET2 #TXNRD1”
— @doctorpemm · BPDCN research updates · View post ↗
“But here is the list of a few CAR-T and systemic treatment options in R/R DLBCL.”
— @OncBrothers · R/R DLBCL treatment options · View post ↗“Outstanding talk on CLL Updates for 2026 by Prof .@NitinJainMD to kick off at @_MDEducation Leukemia meeting”
— @doctorpemm · CLL updates · View post ↗📌 Amplified by @KolPulseAI